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Abstract
It has recently been estimated that a single HIV-1 infected cell produces between 103 and more than 104 viral particles over
its life span. Since body-wide estimates of the ratio of free virus to productively infected cells are smaller than 103 and much
smaller than 104, individual virions must be cleared rapidly. This seems difficult to reconcile with the fact that most of the
total body virus is trapped on follicular dendritic cells where it can survive for many months. It has also been difficult to
reconcile the vast difference in the rates at which the virus is cleared from the blood in rhesus macaques and in chronically
infected patients. Here we attempt to reconcile these seemingly contradictory observations by considering the virion
clearance rate in various organs and the virion exchange rates between them. The main results are that the per capita
clearance rate of free virus in lymphoid tissue should be fast, the virion exchange rate between lymphoid tissue and the
blood should be slow, and the comparatively slow previous estimates for the virion clearance rate from the blood
correspond to the rate of virion efflux from the blood to other organs where the virus is ultimately cleared.
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Introduction
The major targets of HIV and simian immunodeficiency virus
(SIV) infection are CD4z T cells [1]. During the acute stage of
infection large numbers of resting and memory CD4z T cells
disappear from the lymphoid tissues and mucosal layers,
particularly in the gut, by direct infection and by bystander
effects. Lymphoid tissue remains the primary site of infection after
acute infection has resolved and the viral load approaches a steady
state called the ‘‘set-point’’ [1]. Chronic infection is characterized
by a set-point viral load, and rapid turnover of productively
infected cells [2–4]. To maintain this steady state requires a
balance between virus production and clearance, and between
target cell production and death. Combining image analysis with
in situ hybridization in lymphoid tissue from patients chronically
infected with HIV-1, the total number of productively infected
CD4z T cells has been estimated to be 108 cells, and the total
number of HIV-1 particles has been estimated to exceed 5|1010
virions [5,6]. At steady state, one could naively conclude that a
single productively infected CD4z T cell should therefore account
for a viral load of approximately 500 virions. We shall show below
that the situation is more complex.
Tounderstandviralproductionand clearancebetter,oneneedsto
consider the current quantitaive estimates of viral production and
clearance, aswellas where these processes are occurring inthe body.
Mostofthe total bodyvirusislocatedinlymphoidtissues,typicallyin
association with follicular dendritic cells (FDCs) [1,5]. FDCs trap
virus and retain it on their surface for many months [7–11]. The
FDCassociatedviruspoolfillsupduringearlyinfection,i.e.,notlater
than a few days after onset of symptoms, and does not expand over
the course of chronic HIV-1 infection [12]. Although most of the
virus resides in this fairly constant storage on FDCs, the store rapidly
declines during antiretroviral treatment (ARV) [13], suggesting the
existence of a quasi steady state between free and FDC associated
virus in the lymphoid tissue [8–10,14]. In a mouse model it was
shown that a small fraction of HIV-1 persisted on FDCs, and
remained infectious over a period of 9 months [7]. A recent study
confirmed the long-lived nature of this reservoir in humans [11].
Viral clearance rates have been estimated in the blood, and
different techniques have yielded a variety of estimates [4,15–17].
Rapid clearance rates with half-lives of 3–4 minutes were found
after infusion of SIV into the blood of uninfected and infected
rhesus macaques [16,17]. In patients chronically infected with
HIV-1, more than 10-fold slower clearance rates were found using
plasma apheresis to increase viral clearance, and hence perturb the
viral set point [15]. By plasma apheresis approximately 108
particles were removed over a period of two hours, and this
reduced the viral load in blood, with a nadir that was
approximately half of the original viral load [15]. The mere fact
that the removal of less than 1% of the total body virus lead to an
observable decline in the plasma virus load [15], suggests that the
exchange of virus between the lymphoid tissues and the blood
cannot be rapid [14]. Further, sequence analysis of virus in splenic
white pulps suggests that virus trapped on FDC is produced locally
[18], supporting the notion of slow viral exchange between blood
and lymphoid tissue.
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techniques. Because in other lentivirus infections, most notably
visna virus, intracellular viral DNA levels increase approximately
exponentially and then virus appears to be released rapidly [19],
the term burst size is commonly used to describe the total amount
of virus produced by an infected cell [20]. If one knows the burst
size, N, and the average lifespan of a productively infected cell,
1=d, then the viral production rate, p, is given by p~Nd. Note
that p is then the average rate of virion production over the
lifespan of a productively infected cell. Current estimates suggest
d&1 d{1 [21]. Thus, the burst size corresponds to the daily viral
production rate.
Recent studies have combined image analysis with in situ
hybridization to estimate burst size. Assuming that the maximal
HIV RNA count in a cell corresponds to the burst size, Haase et al.
[5] estimated a production rate of approximately a hundred
particles over the life span of a productively infected cell. Hockett
et al. [22] quantified more precisely the amount of viral RNA
(vRNA) per cell by a PCR technique. They found an average of
3900 (range 3162–5011) vRNA copies per infected cell, and
because of limited variation in the number of copies per cell, they
concluded that viral production is a few thousand virions per cell,
and also assumed that bursting was an all-or-none phenomenon
[22]. However, the estimates by Haase et al. [5] and Hockett et al.
[22] are based on measuring HIV RNA at a single time point. If
infected cells continue to produce virus over an extended period,
then these estimates would be underestimates of the true total
cellular production of virus.
One can also attempt to measure burst size by directly imaging
the extracellular viral particles surrounding an infected cell [23].
Using this method, Reilly et al. [23] found 191+89 and 34+12
copies of HIV-1 RNA surrounding infected activated and resting
CD4z T cells, respectively, in the lymphoid tissue of acutely SIV-
infected rhesus macaques. They then fitted a five parameter model
to this data, with three of the parameters describing the rate of viral
production as a function of time since infection (see Methods), and
the remaining parameters describing the rate of exponential decay
of cells producing virus, and the rate of loss of viral particles. Using
this model, they estimated that the half-life of virus located around
CD4z T cells producing virus in lymphoid tissue was approxi-
mately three hours. However, this half-life combined diffusion of
virus out of the local area and true virion clearance [23]. Even if all
loss was due to clearance, a three hour half-life corresponds to a per
virion clearance rate of c~ln(2)=(3=24)~5:5 d{1. With this
estimate, Reilly et al. [23] calculated median production rates of
approximately 1500 and 1400 viral particles per activated cell, and
of approximately 650 and 3400 viral particles per resting cell,
depending on two different assumptions for the half life of
productively infected resting cells (see Methods).
Finally, the most direct estimates for the total amount of virus
produced per infected cell was achieved using single-cycle SIV to
infect PBMC which were placed back in uninfected rhesus
macaques. By measuring the total amount of virus produced and
accounting for clearance, this experiment yielded a total
production of approximately 5|104 (range 1:4|104–1:2|105)
virions per infected cell [24]. Because productively infected cells
have a lifespan of about one day, the cellular burst size estimates of
Chen et al. [24] imply daily production rates of approximately
5|104 virions.
Summarizing, the latest production rate estimates converge on a
few thousand to approximately 5|104 virions per productively
infected cell [22–24]. The production rate estimates of Reilly et al.
and Chen et al. depend on the viral clearance rate, c. The 10-fold
range in the estimated production rates is at least partly due
to differences in the clearance rate used in the calculations. Reilly
et al. [23] estimate that c~5:5 d{1 in lymphoid tissue, while Chen
et al. [24] used a previous estimate of c~23 d{1 in the blood [15].
Since, our main result will be that the clearance of free virus in
lymphoid tissue should be fast, and that the observed clearance
from the blood is not clearance but the rate of efflux to other
organs, we will vary the production rate in our analysis and
consider 103 to 5|104 particles per cell as potential realistic
estimates. Finally, note that different cell types, e.g., infected
macrophages, may have different production rates than infected T
cells. Here we consider that the vast majority of virus is produced
by infected CD4+ T-cells [4,25], and hence use estimates of
production from those cells.
In one earlier modeling study a production rate of several
thousand particles per cell was shown to be consistent with a viral
half-life of 3–4 hours in the lymphoid tissue [14], suggesting that
the recent estimates of 10-fold higher production rates [24] imply
even shorter half-lives. However, large total viral production per
infected cell [22–24] and the short viral half-lives they imply [14],
seem difficult to reconcile with the suggestion that most of the virus
in the lymphoid tissue is long-lived and in association with FDCs
[5]. The problem of balancing production with clearance can be
introduced by a simple calculation that assumes the body is a
single well-mixed compartment. An order of magnitude estimate
for the total number of productively infected cells in a human is
108 cells [5,6]. For a human with a viral load of approximately 105
particles ml{1 of plasma, and an estimated total of 15 liters of
extracellular body water in which virus could distribute, one
estimates that there are a total of *109 free virus particles in
extracellular fluids (i.e., only about 2% of the estimated total body
load) [4]. Requiring steady state in the conventional model for
virus production, i.e., dV=dt~pI{cV~0, with a production rate
of p~104 viral particles per infected cell, I, per day, and a steady
state of V~109 free virus particles and I~108 productively
infected cells, one would need a per virion clearance rate of c~1000
d{1, which is much higher than published estimates for the viral
clearance rate in humans [15], but resembles the rapid clearance
rate observed in rhesus monkeys [17]. Even if p~103 d{1 then
c~100 d{1 is needed to balance production, which is still larger
than the current clearance rate estimate in humans [15].
In this paper we attempt to reconcile the various estimates for
the viral clearance rate, the viral production rate, and the amount
of long-lived virus trapped on FDCs within one modeling
framework in order to test whether there is a consistent
interpretation explaining all observations. To do so we introduce
Author Summary
A human cell that is infected with the AIDS virus HIV-1 may
produce more than 104 new viral particles over its short life
span. In patients chronically infected with HIV-1, one can
estimate that on average there are much less than 104 free
viral particles per productively infected cell. This suggests
that the rate at which individual virus particles are cleared
from the body must be fast. Most of the virus is long-lived,
however, because it is trapped on follicular dendritic cells.
We attempt to reconcile these seemingly contradictory
observations by estimating the virion clearance rate in
various organs, and the virion exchange rates between
them, using a mathematical modeling approach. We find
that individual virus particles are cleared rapidly from the
lymphoid tissue, and that the rate at which virus is
exchanged between lymphoid tissue and the blood is
slow.
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viral clearance in various organs, and estimate the rates at which
virus is exchanged between them.
Results
Clearance of SIV from the plasma
A simple and direct approach to estimate the clearance rate of
virus from the blood is to infuse virus particles into the blood, and
monitor their disappearance by taking frequent blood samples.
Zhang et al. [16,17] administered large amounts of SIV to infected
and uninfected rhesus macaques by an intravenous bolus injection
(1010 to 1011 viral particles), or by constant intravenous infusion
(w108 viral particles min{1). From the rate at which virus was lost
from the plasma afterwards, plasma half-lives of 3–4 minutes were
estimated [16,17]. These half-lives were similar in infected and
uninfected monkeys. Virus did not appear to be lost from the
plasma by binding to erythrocytes, PBMCs, granulocytes, or
platelets because there was no evidence of virion binding to these
cell types [16]. In another experiment, viral clearance in various
organs was tracked by injecting radioactively labeled SIV into
macaques, and measuring the percentage of radioactivity and of
SIV RNA persisting in various organs after two hours [17].
Because 30% of the radioactivity, and only 0.053% of the injected
SIV RNA, was recovered from the liver (see Table 1), it was
concluded that the liver plays a major role in viral degradation
[17].
If most of the viral degradation indeed takes place in organs
such as the liver [17], most of the measured clearance from the
blood would be efflux from the blood into the organs. Therefore,
we write the following simple model for the amount of radioactive
virus in the plasma, VP, and in a particular organ, VO,
dVP
dt
~{eVP and
dVO
dt
~efVP{cOVO, ð1Þ
where e is the daily efflux from the blood, f is the fraction that
arrives in the particular organ, and cO is rate of clearance in the
organ. We neglect the flux from the organ back to the blood
during this 2 hr experiment because this simplifies the analyses,
but also because the results of the bolus injection and the
continuous virus infusion experiments [16,17], yielded similar
disappearance of virus from plasma in uninfected and already
infected monkeys, indicating that this flux is very small in these
short-term experiments.
If VP(0) is the total amount of virus injected into the plasma,
then
VP(t)~VP(0)e{et and VO(t)~VP(0)
ef
cO{e
e{et{e{cOt ðÞ : ð2Þ
After two hours, the fraction of infused viral RNA found in the
organ is
VO
VP(0)
~
f(e{cO(2=24){e{e(2=24))
1{cO=e
, ð3Þ
where the 2=24 converts 2 hrs into a per day timescale. The
fraction of radioactivity ending up in the organ after the two hour
experiment, RO, is assumed to be equal to the fraction of virus
entering (and presumably degraded in) that organ, i.e.,
RO~
ðt~(2=24)
t~0
efe{etdt~f(1{e{e(2=24)): ð4Þ
Using the estimated clearance rate from the blood of 0.2 min{1
[17] as the efflux rate, e~288 d{1, we estimate the fraction, f,a n d
theclearanceintheorgan,cO, from the Zhang etal.[17]data shown
in Table 1. Since in Eq. (4) the term e{288|(2=24)^0, the fraction of
measured radioactivity in the organ, RO, determines the parameter
f in the model. Substituting the fraction of SIV RNA in the organ,
VO=VP(0), the estimated efflux, e, and the fraction of radioactivity,
RO, into Eq. (3), one can numerically solve for the clearance rate
constants, cO, in the four organs (Table 1). The estimated clearance
rates in the various organs vary from cO^80 d{1 in the liver to
cO^10 d{1 in the lymph nodes. The latter is only 2-fold faster than
the clearance rate of c~5:5 d{1 estimated by Reilly et al. [23] for
lymphoid tissue.
Only 40.5% of the total radioactivity was recovered in the
monkey 2 hr after injection. This could be due to a loss of
radioactivity by viral degradation and removal of labeled
molecules, or to accumulation of SIV in other body compart-
ments, such as the gastrointestinal tract, that were not examined
[17]. The former we can correct for by re-normalizing the
radioactivity data so that the total is 100%. This correction
doubles the estimate clearance rate in lymph nodes, and has a
smaller effect on the other clearance rates (see Table 1). If the virus
unaccounted for by the radioactivity data is ending up in other
organs, the clearance rates based upon the uncorrected radioac-
tivity data should be valid. Interestingly, percentages of SIV RNA
were also measured in ileum, cecum, duodenum and rectum in
other monkeys, and adding these data from the gut to the
‘‘Others’’ class hardly increased the amount of SIV RNA in that
class [16]. This would argue that only a minor fraction of the
injected virus ends up in the gastrointestinal tract, and/or that the
clearance rate in the gastrointestinal tract is much larger than in
the other organs so that SIV RNA is not found there.
Unfortunately, there is no radioactivity data for the gastrointestinal
Table 1. The fraction of a bolus injection of SIV going into an
organ after two hours, and the clearance rate in that organ
estimated by Eqs. 3–4.
measured normalized
Organ % RNA RO cO (d{1) ^ RO ^ c cO (d{1) half life
Liver 0.053 0.295 79.75 0.728 91.28 10.9–12.5 min
Lung 0.154 0.054 44.71 0.133 56.10 17.8–22.3 min
Spleen 0.077 0.004 20.66 0.010 32.19 31.0–48.3 min
Lymph
nodes
a
1.380 0.030 9.73 0.074 21.06 47.4–
102.6 min
Others
b 0 v0:022 – 0.054 – –
Total 1.664% 0.405 – 1.0 – –
Data from Zhang et al. [16,17]: for the indicated organs the fraction, RO,o f
injected radioactivity was measured in an uninfected rhesus macaque (animal
AR97), and the percentage of injected SIV RNA was measured in another
uninfected macaque (animal 1336). The % RNA column corresponds to the
100VO=VP(0) of Eq. (3). From this data we compute the clearance rate in the
organ, cO, and the corresponding half-life. Because in total only 40.5% of the
radioactivity was recovered, we also re-normalize the radioactivity data
(assuming that part of the radioactivity has disappeared by degradation of the
labeled molecules). The ranges in the half life column are obtained from the
corrected and the uncorrected radioactivity data, respectively.
aLymph nodes were assumed to be 1% of the total body weight.
bmeasured in heart, kidney, muscle, pancreas, brain and tonsil.
doi:10.1371/journal.pcbi.1000906.t001
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the viral half-lives in the various organs by the ranges indicated in
Table 1, as obtained from the corrected and the uncorrected
radioactivity data, respectively. Summarizing, modeling the
radioactivity data provides estimates of viral clearance rates
between c~10 d{1 and c~91 d{1 in various organs (Table 1).
Plasma apheresis
HIV-1 clearance rates from plasma have been estimated in
chronically infected patients by plasma apheresis over a period of
two hours. Plasma was removed at a rate of 39 mL per min, and
was replaced by an equivalent volume of isotonic saline containing
5% albumin. On average, this procedure removed a total of
approximately 108 particles, and resulted in a nadir of virus equal
to half the initial viral load [15]. The following model, formally
equivalent to the one presented in Ramratnam et al. [15], was used
to fit the data:
dVP
dt
~s{(ezE)VP, ð5Þ
where s is the rate of virus influx from the lymphoid tissue, e is the
normal efflux from the blood, and E is the additional rate of virus
removed from the blood due to plasma apheresis. It was assumed
that over the course of the two hour experiment the flow of virus
into the blood, s, remains constant, and it was found that the rate
of viral efflux in four patients ranged from e~9 to 36 d{1, with an
average of e~23 d{1 [15]. The rate of virus influx, s, at steady
state is estimated by multiplying the plasma efflux rate, e, by the
initial virus load, and varies from s~4:6|108 to s~3:5|109
particles d{1, with an average of s~2|109 particles d{1. The
mere fact that the removal of less than 1% of the total body virus
over a period of two hours led to significant declines in the plasma
virus load (Table 2 and Ramratnam et al. [15]), suggests that the
plasma virus pool is not rapidly replenished from the lymphoid
tissue or other organs[14]. This observation also supports our
neglecting virus return from organs back into the plasma in Eq. (1).
It is worth noting that the estimate for the efflux rate in humans
of HIV-1 from plasma is more than 10-fold slower than the
estimated plasma efflux rate of SIV in rhesus monkeys [15–17],
which could reflect a true difference between these two species.
Alternatively, it could be that the plasma clearance rate in the four
patients studied by Ramratnam et al. [15], all of which had high
viral loads, is slower than in the monkeys studied which had much
lower viral loads [16,17]. A potential mechanism for the more
rapid clearance in monkeys with low viral load could be the rapid
attachment of virus to various receptors on blood born cells,
whereas in patients with chronic high viral loads these receptors
could be saturated and bind less virus (see Discussion).
Clearance of virus from lymphoid tissue
Since most virus production takes place in the lymphoid tissue,
we modify a previously published compartmental model [14] to
rewrite the fixed source s in Eq. (5) into a term depending on the
amount of virus in lymphoid tissue (LT). We proceed by
considering four viral compartments: virus in organs other than
LT, VO, virus in the plasma, VP, free virus in the lymphoid tissue,
VF, and virus bound to FDCs in lymphoid tissue, VB. The model
has two clearance rates, c and cO, for the rate of clearance of free
virus in LT, and in other organs (like the liver and lung),
respectively. As before, there is no clearance in blood. Virus bound
to FDCs is considered to be long-lived [7], and virus in the plasma
is considered to be lost by migration to organs or LT. We allow for
influx of free virus into the plasma from the LT with rate constant
i, because now we are modeling a long term process, and efflux
from the plasma with rate constant e. A fraction f of the virus
leaving the plasma will return to the LT, the rest is cleared in
organs like the liver and lung. This compartment model is
represented by the following equations:
dVO
dt
~(1{f)eVP{cOVO, ð6Þ
dVP
dt
~iVF{eVP, ð7Þ
dVF
dt
~pIzfeVP{(izc)VF{k1VF(F{VB)z^ k k2VB, ð8Þ
dVB
dt
~k1VF(F{VB){^ k k2VB, ð9Þ
where I is the number of productively infected cells in the LT.
In this model we make a distinction between clearance and
efflux. We speak of efflux when the number of virus particles is
conserved, and speak of viral clearance in an organ only if the
virus is being degraded there. Thus, these equations assume that
there is no viral clearance from the blood; there only is efflux to the
lymphoid tissue and to other organs that have viral clearance rates,
c and cO, respectively. Mixing SIV with fresh blood taken from
monkeys provided no evidence for viral degradation within plasma
ex vivo [17], and for several viruses most of the clearance takes
place in liver and spleen [16]. The model can easily be modified to
allow for viral clearance from the blood, e.g., by decreasing the
(1{f) term in Eq. (6). This would not affect our results, however,
Table 2. The plasma apheresis data from Ramratnam et al.
[15].
Patients 1 2 3 4
Duration (min) 78 120 136 116
Total plasma
volume (ml)
a
3549.3 3709.5 4048.2 4332.9
Plasma removed
(ml)
2972 2974 5319 3477
Baseline HIV load
(total plasma)
1:77|107 3:7|107 4:0|108 8:4|107
Total virus
removed
2:3|107 3:9|107 4:8|108 5:0|107
Efflux rate (e:d {1) 25.9 21.6 8.64 36.0
Extra efflux
rate (E:d {1)
15.5 9.6 13.9 10.0
Total influx (s:
particles d{1)
b
4:6|108 8:0|108 3:5|109 3:5|109
Predicted nadir 1:18|107 2:65|107 1:93|108 6:58|107
Average clearance rate from blood   e e~23 d{1 and average influx into blood
  s s~2:1|109 particles d{1.
aEstimated from body weight (44 ml/kg).
bEstimated by clearance rate | baseline HIV load (given in particles, i.e., HIV
RNA/2).
doi:10.1371/journal.pcbi.1000906.t002
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three compartments of the model. Technically, the ‘‘viral
clearance’’ rates from the blood estimated previously by the
apheresis [15] and infusion [16,17] experiments, cannot distin-
guish between clearance and efflux, and we will let these estimates
represent the efflux rate, e, in Eq. (7).
The parameter ^ k k2 in Eqs. (8) and (9) is the average dissociation
rate of virus bound to FDCs. F is the maximum number of
binding sites on FDCs that HIV-1 can attach to, and k1 is the rate
constant for the association of virus with an FDC binding site.
These binding sites include complement receptors and Fc
receptors [8], and possibly other receptors like DC-SIGN [26].
The dissociation process is complicated and depends on the
number of bonds by which virus is bound to the FDC [8]. When
VB%F most virus particles have multiple bonds holding the virus
to FDC, which makes the dissociation slow, and probably accounts
for the long half-life of a fraction of the bound virus [7,8,11].
When VB is large most viruses will have few bonds holding them to
FDC and dissociation should be more rapid. We can describe this
phenomenologically with a Hill-function such that the effective
virion dissociation rate constant ^ k k2 increases with VB
^ k k2~
k2Vn
B
(wF)
nzVn
B
, ð10Þ
where n and w are constants with wƒ1, and ^ k k2~k2=2 when
VB~wF.
In a typical patient the FDC pool seems saturated, i.e., VBwwF,
and most virus is expected to be monovalently bound with a
dissociation rate estimated as ^ k k2^0:1/sec [8]. Image analysis
combined with in situ hybridization suggested that most of the virus
in the lymphoid tissue is associated with the FDC network [5]. The
FDC associated virus, VB, fills up early in infection [12]. During
chronic infection we therefore assume dVB=dt~0, and this large
pool of FDC associated virus is viewed as a filled store in quasi
steady-state that contributes little to the total body viral clearance.
When the FDC pool is close to being saturated, the steady state of
Eqs. (6) to (9) corresponds to
VO~
(1{f)eVP
cO
, VP~
iVF
e
, VF~
pI
i(1{f)zc
and
VB~
F
1z
^ k k2
k1VF
,
ð11Þ
where VF^pI=c if c&i(1{f), and VB^F if ^ k k2=(k1VF)%1.
To consider the total virus load we add Eqs. (6)–(9) yielding,
dV
dt
~pI{cOVO{cVF, ð12Þ
where V~VOzVPzVFzVB is the total body virus load. For a
chronically infected patient assumed to be in a steady state we
substitute VO~(1{f)eVP=cO~(1{f)iVF=cO from Eq. (11) to
obtain
dV
dt
~pI{½(1{f)izc VF~0, ð13Þ
where the total body clearance rate, (1{f)izc, is the total steady
state rate of clearance taking place in organs like the liver and the
lymphoid tissues. Since our aim is to estimate c, we rewrite Eq. (13)
as
c~p
I
VF
{(1{f)i~p
I
VF
{(1{f)e
VP
VF
, ð14Þ
where we have again used VP~iVF=e from Eq. (11).
We can use the relationships between c and the steady state
levels in Eq. (14) to study what clearance rates would be required
to balance production in a number of typical situations. Since
there is ambiguity on the rate of efflux from the blood, e, we use
the efflux estimates from the plasma apheresis experiments [15],
i.e., e~9 to 36 d{1, and from the rhesus monkeys [16,17], i.e.,
e~288 d{1, as lower and upper bounds to create examples of how
viral production and clearance could be balanced in hypothetical
patients. If we use a middle value for the fraction of plasma virus
returning to the LT, e.g., f~0:5, we obtain an upper estimate of
(1{f)e^0:5|288^150 d{1 and take a lower estimate of
(1{f)e^25 d{1. To estimate the ratios between the variables
in Eq. (14) we pick an example of a patient in a chronic steady
state with total body counts of I~108 productively infected cells,
VP~108 virus particles in the peripheral blood, and
VFzVB~1011 virus particles in the lymphoid tissue. Finally,
because Hockett et al. [22] did not detect virus associated with
FDCs in almost half of their patients, and measured 10-fold higher
total amounts of virus in lymph nodes from those patients where
they could detect virus on FDC, we consider two possibilities. To
model a ‘‘typical’’ patient where most of the virus is associated
with FDCs, we let 90% of the lymphoid tissue virus be associated
with FDCs, and obtain that VF~1010. To model patients with a
smaller pool of FDC associated virus, we also consider the
possibility that half of the LT virus is bound to FDCs, i.e.,
VF^VB, which amounts to VF~5|1010. This allows us to study
how the estimates for the viral clearance rate in LT depend on the
fraction of virus bound to FDCs.
For the more ‘‘realistic’’ example, Fig. 1a, where most of the
virus is associated with FDCs, our estimate of the per capita
clearance rate in LT, c, depends strongly on the production rate p,
and a large production rate, e.g., pw1000 virions per cell per day,
requires rapid clearance of virus in the lymphoid tissue, i.e., cw10
per day to maintain a steady state level of virus (Fig. 1a). The
recently proposed production rates of more than 104 viral particles
per infected CD4z T cell would require LT clearance rates of
cw100 per day (Fig. 1a). When Chen et al. [24] estimated these
high production rates they were conservatively assuming that
c~23 d{1. Because their estimated production is proportional to
the assumed clearance rate, our new results suggest that the true
production could be even higher. In cases where less virus is
associated with FDCs (Fig. 1b), we find a similar relation between
the clearance rate in LT, c, and the production rate, p, but the
required clearance rate c is approximately 5-fold smaller because
we allow for 5-fold more free virus, i.e., VF~5|1010 (Fig. 1b). In
this case, for realistic virion production rates per cell, e.g., pw1000
per day, the estimated clearance rate c is fairly independent of rate
of efflux from the blood ((1{f)e); see Fig. 1.
The viral exchange rate between lymphoid tissue and
blood
Analysis of the plasma apheresis experiments in humans
provided estimates for the influx of virus from the LT into the
blood (Table 2). This can also be calculated from the quasi steady
state of Eq. (7), i.e., for the influx of virus from the LT into the
blood, one obtains that
i~e
VP
VF
, ð15Þ
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in patients and macaques, respectively. For the case when 90% of the
lymphoid tissue virus is associated with FDCs, i.e., VP=VF~0:01,t h i s
means that 0:23viv2:88 d{1. Assuming an equal distribution of free
and FDC-bound virus in lymphoid tissue, i.e., VP=VF~0:002,o n e
obtains 0:046viv0:576 d{1. Taking these two cases as extremes, the
daily influx of virus from the lymphoid tissue into the blood would be
between 2:3|109viVFv2:88|1010 virus particles per day, i.e.,
about 108 to 1:2|109 particles per hour. These estimates are in good
agreement with the daily influx estimated from the plasma apheresis
experiments (Table 2). Finally, for these estimates of i, the clearance
rate in LT should approach c~pI=VF as the term (1{f)i in Eq. (14)
is negligible.
To test whether the full model (Eqs. 6–9) is consistent with the
plasma apheresis experiments, we make reasonable guesses for the
other parameters of the model. Allowing rapid filling of the pool of
virus bound to FDCs we set the number of FDC binding sites
F~1011 and k1~2:4|10{9 d{1. With these parameters the
initial ‘‘on’’ rate when all FDC sites are free is k1F~8:64|105 d{1
(10 s{1). To have 100-fold more free virus in LT than in blood, i.e.,
e=i~100 (seeEq.(11)),we seti~0:24 d{1 and e~24 d{1. Tohave
about pI=c~1010 free virus particles inthe LT, we set pI~5|1011
particles d{1 and c~48 d{1 (see Eq. (11)). During a two hour
plasma apheresis experiment we transiently add an estimated efflux
of E~12 d{1 during apheresis to Eq. (7) (like we do in Eq. (5)). For
these parameters the model results mimic the plasma apheresis
experiments in the blood (Fig. 2a), reducing the viral load in plasma
by 30% and accumulatinga total of 8|107 virus particles. Free and
bound virus in LT are hardly affected (Fig. 2b). Very similar results
areobtained whenweincreaseproduction and viralclearanceinthe
LT 10-fold to pI~5|1012 particles d{1 and c~480 d{1 (not
shown). Explaining the plasma apheresis experiments in humans
therefore indeed requires a viral efflux half-life from the plasma of
about half an hour [15].
Choosing the efflux rates estimated in monkeys [16,17], we have
also set i~2:4 d{1 and e~240 d{1, which delivers a very similar
steady state as that shown at time zero in Fig. 2. Simulating plasma
apheresis by setting E~12 d{1 for two hours a total of 9:5|107
virions are removed, but the plasma virus load decreases by 5%
only (not shown). This is a natural result because the additional
clearance of E~12 d{1 is small compared to the normal efflux
from the plasma of e~240 d{1. We therefore predict that if
plasma apheresis experiments were repeated in SIV infected
rhesus macaques, the viral load in the plasma would hardly be
affected.
Discussion
We have shown that the balance between viral production and
viral clearance implies rapid per capita viral clearance rates in
lymphoid tissues. The larger the viral production rate per
productively infected cell, and the more virus that is bound to FDCs
(see Fig. 1), the larger the per capita c l e a r a n c er a t eo ff r e ev i r u si n
lymphoid tissue mustbe tobalance viral production. Recent estimates
of a burst size up to 5|104 virions per cell and a productively
infected cell life span of about a day [21,24], imply viral clearance
rates in the lymphoid tissue of c~50 to c~500 d{1 (Fig. 1).
In our modeling work the rate of virion clearance, c, is assumed
to be a constant. This is equivalent to assuming that clearance
occurs by a first-order process or that virus clearance can be
described by an exponential decay. However, it is possible that
viral clearance obeys more complex laws. Comparing viral loads in
lymph nodes and plasma from 9 patients at relatively advanced
stages of disease, Hockett et al. [22] demonstrate that the plasma
viral load increases faster than proportional with the number of
productively infected cells. One possible explanation is that the
viral clearance rate decreases or saturates when the viral load
increases. However, this explanation remains speculative as it
requires a 100-fold decrease in the clearance rate at their highest
Figure 1. Viral clearance in the lymphoid tissue, c, as a function of the production rate p, given by Eq. (14), for a typical patient with
I~108 cells, VP~108, VL~VFzVB~1011 particles, and the indicated clearance rates via the blood, (1{f)e. In (a) 90% of the virus in
lymphoid tissue is associated with FDCs, i.e., VF~1010, and in (b) this is 50%, i.e., VF~5|1010.
doi:10.1371/journal.pcbi.1000906.g001
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variation in the clearance rate [22].
The efflux and/or clearance rate of SIV from the blood of
uninfected monkeys and of infected monkeys with a low viral load
[16,17] is about 10-fold higher than that of HIV-1 measured by
plasma apheresis experiments in chronically infected patients
[15]. Because the additional removal (E in Table 2) realized in the
plasma apheresis experiments is also 10-fold smaller than these
efflux rates in monkeys, plasma apheresis would have hardly any
effect if humans were to have efflux rates similar to these monkeys
(this expectation was confirmed by computer simulation). As
discussed above this 10-fold difference in the estimated efflux rate
from the plasma could reflect a true species difference. A
speculative alternative is that efflux from the plasma hinges upon
attachment of virus to various receptors on blood born cells, like
CCR5 and CD4 on various cell types, gp340 on macrophages
[27], DC-SIGN on dendritic cells [26] and DARC on red blood
cells [28,29]. Because the monkeys in these experiments had
much lower viral loads than the four patients studied by apheresis
[15–17], most of the receptors could be free in monkeys and
occupied with HIV-1 in chronically infected humans with a high
viral load. However, this remains speculative because Zhang et al.
[16] found negligible amounts of virus on erythrocytes, peripheral
blood mononuclear cells (PBMC), granulocytes, and platelets.
Moreover, note that the estimated clearance rate in the liver, the
organ that appears to be responsible for most of the peripheral viral
degradation [17], is reasonably close to the high clearance rates of
free virus in lymphoid tissue that we estimate to be required for
balancing the total body virus production.
Finally, it may seem that the notion of a large FDC store of
bound virus is incompatible with the rapid viral clearance rates
seen in spleen and lymphoid tissues of uninfected macaques
[16,17]. In other words, if the FDCs were trapping and
maintaining the virus in lymphoid tissues, then after radiolabeled
virus was injected, the percentages of radioactivity and SIV
RNA found in these tissues should have been similar, whereas a
2-fold difference was observed, i.e., 3% vs. 1.4% (Table 1).
There are at least two possible explanations for this difference.
First, virus is reversibly bound to FDC [8] so radiolabeled virus
could dissociate and the virus could then be degraded.
Alternatively, the clearance after bolus infusion of SIV in
monkeys was studied over a time window of just two hours
[16,17], and one could speculate that most of the added virus in
these short experiments fails to bind FDCs, and could therefore
be cleared rapidly.
Rapid viral clearance in lymphoid tissue is not surprising. The
lymphoid tissue contains more than 1011 CD4z T cells, i.e., the
ratio of virus to CD4z cells in the LT is approximately 1:1, and
virus particles will bind CD4z T cells and macrophages, and
defective virus particles will be ‘‘cleared’’ by non-productive
infection. Phagocytic cells that are also abundantly available in LT
may clear virus via various types of receptors, like Fc, complement,
and DC-SIGN on dendritic cells [26]. Since the process of virus
binding cell surface receptors is relatively fast, it can readily
account for the rapid clearance rates that we derive from
balancing total body production with total body clearance. Finally,
during chronic HIV-1 infection the long-lived pool of virus on
FDCs should be in steady state, and thus not contribute to the
actual clearance rate of the virus in lymphoid tissue (see Eq. (12)).
In a previous paper we showed that the rate of viral clearance in
lymphoid tissue would markedly affect the estimated life span, 1=d,
of productively infected cells deduced from antiretroviral drug
therapy (ART) experiments, if the clearance rate in lymphoid
tissues were sufficiently slow [14]. Since we now estimate even
higher clearance rates than we did previously, it becomes even
more likely that the clearance from lymphoid tissue is sufficiently
fast to not affect the accuracy of current estimates of d, the death
rate of productively infected cells. Having c&d, one expects the
loss of productively infected cells to be the dominant slope of viral
decline during the first week or two of ART [14]. The amount of
virus in the blood, free virus in lymphoid tissue, and virus on FDCs
should be in quasi steady state with the loss of productively
infected cells, which is in good agreement with the rate of about
0.5 per day at which virus in lymphoid tissue declines during ART
[13]. When the amount of virus on FDCs has dropped
significantly, most of the remaining virus will be attached by
Figure 2. Plasma apheresis for 2 hrs simulated in the model for a patient with VP^108, VF^1010 and VB^1011 virus particles in the
total body. The solid line is the plasma viral load (VP). The discontinuities reflect the time period of plasma apheresis which starts at time zero and
continues for two hours (during this period we set E~12 d{1; otherwise E~0). The dashed line in (a) is the total amount of virus removed (VR), i.e.,
the solution of dVR=dt~EVP. The dashed line in (b) is virus bound to FDCs (VB), and the dash-dotted line in (b) is free virus in lymphoid tissue (VF).
Parameters: w~1, F~1011, c~48 d{1, e~24 d{1, E~12 d{1, f~0:1, i~0:24 d{1, k1~8:64|10{6 d{1, k2~8640 d{1 (0.1s{1), n~1, pI~5|1011
particles d{1. The results in this Figure are independent of the parameter cO because we are only solving for VP, VF, and VB (see Eqs. 7–9).
doi:10.1371/journal.pcbi.1000906.g002
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lives of virus on FDCs during ART [7].
Summarizing, we have provided new estimates of viral efflux
and clearance rates in various organs, including blood and
lymphoid tissue. We have confirmed that the exchange rate from
lymphoid tissue to the blood should be slow [14]. Whenever viral
production rates exceed 103 virus particles over the life time of a
productively infected cell [22–24], we estimate clearance rates in
lymphoid tissue of 10–100 d{1 for typical situations where most of
virus in lymphoid tissue is associated with FDCs.
Methods
Reilly et al. [23] fitted data obtained by in situ hybridization in
lymphoid tissue, including measurements of the number SIV RNA
copies on the surface of and in the vicinity of activated and resting
CD4z T cell in lymphoid tissue of acutely SIV-infected rhesus
macaques, with averages of 191:1+88:6 and 33:7+12:1 copies
per cell. Although the data were static, i.e., they were single snap-
shots of different cells not containing any information on the time
since infection of the cells, the data was fit to a dynamic model
with a Bayesian approach using simulated annealing to find the
most likely parameter values [23]. The model consisted of a three
parameter viral production function (see Fig. 3, i.e., intercept, up-
slope, and saturation time, and two parameters for the exponential
decay of cells producing virus, and loss of viral particles,
respectively [23]. The prior distribution for the half-life of
activated infected cells was fixed to a mean of 1.5 days, whereas
having little information on the expected life span of productively
infected resting cells, two different prior distributions for the half-
life of resting infected cells were chosen, with means of 4 days
(Fig. 3a & b) and 14 days (Fig. 3c & d), respectively.
To estimate viral production rates per virus producing cell from
this data, one has to integrate the virus production function over
the life span of the cells. Reilly et al. [23] estimated the median
production rate by integrating up to the estimated half-life of the
cells (see the heavy lines in Fig. 3), and this yielded median
production rates of 1479 and 1395 viral particles per activated
Figure 3. Viral production rates in the lymphoid tissue estimated by Reilly et al. [23] for resting (panels a,c) and activated cells (b,d)
respectively. The top row of the Figure (Panels a,b) is the result when the mean of the prior distribution of the half-life resting cells is 4 days (and
that of activated cells is 1.5 days). In the bottom row (c,d) the mean of the prior distribution of the half-life resting cells is 14 days (and that of
activated cells remains 1.5 days). The median total production rate per cell is computed by integrating these curves up to the half-life of the cell (as
indicated by the heavy lines) and amounts to 1479 and 1395 virions per activated cell and 644 and 3405 per resting cell (see the text). The horizontal
and vertical lines marked by crosses denote the mean value with 95% credible intervals for the production rate at time zero, the half-life of the cell,
and the saturation time of the production function [23].
doi:10.1371/journal.pcbi.1000906.g003
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respectively), and of 644 and 3405 viral particles per resting virus
producing cell (Fig. 3a & c, respectively).
Note that the estimates obtained in Fig. 3 are independent of the
estimated time to saturation, and largely depend on the intercept
and slope of the virus production function (Fig. 3). In three of the
four panels the heavy black line, reflecting the period over which
virus production was integrated, stops well before the saturation
point. This is reassuring because the 95% credible intervals on the
saturation time are very large. Indeed, these data can hardly
support the existence of a saturation time in the production curve
because the estimated saturation time is much larger than the
estimated half-life of the cells. Thus, the data must have had
virtually no cells that became old enough to breach the saturation
time, and therefore the data hardly contains any information on
possible saturation effects. This implies that the estimated
saturation times were largely determined by the prior distribution
of the Bayesian parameter estimation procedure. Fortunately, for
the interest of this paper, eliminating the saturation barely affects
the estimated production rates.
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